Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study

CONCLUSIONS: There was no significant difference in CGI-I-AS between gaboxadol and placebo after 12 weeks of study treatment in pediatric AS participants.CLINICALTRIALS: GOV: NCT04106557.PMID:37639777 | DOI:10.1016/j.ejpn.2023.07.008

Source: European Journal of Paediatric Neurology - August 28, 2023 Category: Neurology Authors: Christopher Keary Lynne M Bird Marie-Claire de Wit Shivkumar Hatti Gali Heimer Helen Heussler Alexander Kolevzon Adera Mathews Cesar Ochoa-Lubinoff Wen-Hann Tan Ying Yan Maxwell Adams Source Type: research